Skip to main content
H

Hunan Warrant Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 688799 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 717 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688799

About Hunan Warrant Pharmaceutical Co., Ltd.

Hunan Warrant Pharmaceutical Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and distribution of chemical APIs and finished dosage forms. The company specializes in chiral drug technology and complex chemical synthesis, maintaining a robust portfolio that includes digestive system medications, cardiovascular treatments, and anti-infective agents. Key products include esomeprazole sodium and other high-end generic formulations. Warrant Pharmaceutical operates integrated R&D platforms and manufacturing facilities compliant with international quality standards, aiming to provide cost-effective therapeutic solutions. Its core competencies lie in the development of high-barrier generic drugs and the industrialization of advanced chiral synthesis processes, serving both domestic and international healthcare markets.

Recent filings

Filing Released Lang Actions
关于2026年度对外提供担保额度预计的公告
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement by Hunan Warner Pharmaceutical Co., Ltd. concerning the board’s approval of the 2026 external guarantee limit for its subsidiary. It details guarantee amounts, decision procedures, risk disclosures, and the board’s resolution. It is not an earnings release, financial report, management change notice, or investor presentation, nor is it the publication of a report. Rather, it is a standard compliance/regulatory disclosure under listing rules regarding guarantees. Therefore, it falls into the fallback category of general Regulatory Filings (RNS).
2026-04-20 Chinese
董事会薪酬与考核委员会关于公司2024年限制性股票激励计划第一个归属期归属名单的核查意见
Share Issue/Capital Change Classification · 1% confidence The document is a formal board committee opinion from Hunan Warner Pharma’s Board Compensation and Assessment Committee on the vesting list for the company’s 2024 restricted stock incentive plan first vesting period. It specifies the total number of shares (2.317 million shares) to be issued upon vesting and confirms compliance with relevant laws and the company’s articles of association. This is an announcement of a share issuance under an employee incentive plan, fitting the definition of a Share Issue/Capital Change (SHA).
2026-04-20 Chinese
独立董事2025年度述职报告（康彩练）
Regulatory Filings Classification · 0% confidence The document is the 2025 Annual Duty Performance Report of an independent director at a Chinese listed company. It is not an earnings release, quarterly/interim report, or an annual report itself, nor an announcement of a meeting or vote. It does not report a board change but rather details the independent director’s activities, governance oversight and adherence to regulations. There is no precise matching category in our taxonomy, so it falls into Regulatory Filings (RNS) as a miscellaneous governance‐related submission.
2026-04-20 Chinese
董事会关于独立董事独立性情况评估的专项意见
Governance Information Classification · 1% confidence The document is a board-issued opinion on the independence of its independent directors, discussing governance rules and compliance with the company’s articles and regulatory governance guidelines. It does not announce any director changes or financial data, but rather addresses internal governance practices around independent director independence. This aligns with the Governance Information category.
2026-04-20 Chinese
独立董事2025年度述职报告（吴淳）
Governance Information Classification · 1% confidence The document is titled “Independent Director 2025 Annual Work Report” and contains the independent director’s self-assessment of duties, attendance at board and committee meetings, exercise of independent powers, communications with auditors and shareholders, and governance oversight. It is not an announcement of a change in management nor an MD&A of financial results. Instead, it is a governance‐related report on board practices and independent oversight. Therefore, it best fits the Governance Information category (CGR).
2026-04-20 Chinese
国投证券股份有限公司关于湖南华纳大药厂股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 1% confidence The document is a detailed compliance review (“核查意见”) by the sponsor (国投证券) regarding the specific use of temporarily idle raised funds (募集资金) for cash management by a listed company. It is not an annual or interim financial report, earnings release, board change notice, or any standard template (e.g., 10-K, IR, ER, AGM, DIRS, etc.). It constitutes a regulatory compliance filing under Shanghai Stock Exchange and CSRC rules, serving as an official review opinion on the use of raised funds — a type of general regulatory announcement. Therefore, the appropriate category is Regulatory Filings (RNS).
2026-04-20 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.